1887
Outbreaks Open Access
Like 1

Abstract

In March 2023, 34 associated cases of iatrogenic botulism were detected in Germany (30 cases), Switzerland (two cases), Austria (one case), and France (one case). An alert was rapidly disseminated via European Union networks and communication platforms (Food- and Waterborne Diseases and Zoonoses Network, EpiPulse, Early Warning and Response System) and the International Health Regulation mechanism; the outbreak was investigated in a European collaboration. We traced sources of the botulism outbreak to treatment of weight loss in Türkiye, involving intragastric injections of botulinum neurotoxin. Cases were traced using a list of patients who had received this treatment. Laboratory investigations of the first 12 German cases confirmed nine cases. The application of innovative and highly sensitive endopeptidase assays was necessary to detect minute traces of botulinum neurotoxin in patient sera. The botulism notification requirement for physicians was essential to detect this outbreak in Germany. The surveillance case definition of botulism should be revisited and inclusion of cases of iatrogenic botulism should be considered as these cases might lack standard laboratory confirmation yet warrant public health action. Any potential risks associated with the use of botulinum neurotoxins in medical procedures need to be carefully balanced with the expected benefits of the procedure.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.23.2300203
2023-06-08
2024-02-22
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.23.2300203
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/23/eurosurv-28-23-2.html?itemId=/content/10.2807/1560-7917.ES.2023.28.23.2300203&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Surveillance Atlas of Infectious Diseases. Stockholm: ECDC. [Accessed: 9 May 2023]. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases
  2. Peck MW, Smith TJ, Anniballi F, Austin JW, Bano L, Bradshaw M, et al. Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins (Basel). 2017;9(1):E38.  https://doi.org/10.3390/toxins9010038  PMID: 28106761 
  3. Rossetto O, Pirazzini M, Fabris F, Montecucco C. Botulinum neurotoxins: mechanism of action. Handb Exp Pharmacol2021;263:35-47.  https://doi.org/10.1016/S0072-9752(07)01511-4  PMID: 18631849 
  4. Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333-68.  https://doi.org/10.1016/S0072-9752(07)01511-4  PMID: 18631849 
  5. Smith T, Williamson CHD, Hill K, Sahl J, Keim P. Botulinum neurotoxin-producing bacteria. Isn’t it time that we called a species a species? MBio. 2018;9(5):e01469-18.  https://doi.org/10.1128/mBio.01469-18  PMID: 30254123 
  6. Li Y, Liu T, Luo W. Botulinum neurotoxin therapy for depression: Therapeutic mechanisms and future perspective. Front Psychiatry. 2021;12:584416.  https://doi.org/10.3389/fpsyt.2021.584416  PMID: 33967844 
  7. Chiu SY, Burns MR, Malaty IA. An update on botulinum toxin in neurology. Neurol Clin. 2021;39(1):209-29.  https://doi.org/10.1016/j.ncl.2020.09.014  PMID: 33223084 
  8. Dressler D. Clinical pharmacology of botulinum toxin drugs. Handb Exp Pharmacol. 2021;263:93-106.  https://doi.org/10.1007/164_2019_273  PMID: 32886157 
  9. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.  https://doi.org/10.2340/16501977-0303  PMID: 19197564 
  10. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: A review of the evidence. Biologics. 2014;8:227-41. https://doi.org/ 10.2147/BTT.S65603 PMID:25336912  PMID: 25336912 
  11. Kollewe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm (Vienna). 2015;122(3):427-31.  https://doi.org/10.1007/s00702-014-1278-z  PMID: 25059456 
  12. Doan TN, Kuo MY, Chou LW. Efficacy and optimal dose of botulinum toxin A in post-stroke lower extremity spasticity: a systematic review and meta-analysis. Toxins (Basel). 2021;13(6):428.  https://doi.org/10.3390/toxins13060428  PMID: 34207357 
  13. Chang PC, Jhou HJ, Chen PH, Huang CK, Chiang HH, Chen KH, et al. Intragastric botulinum toxin A injection is an effective obesity therapy for patients with BMI > 40 kg/m2: a systematic review and meta-analysis. Obes Surg. 2020;30(10):4081-90.  https://doi.org/10.1007/s11695-020-04842-4  PMID: 32734569 
  14. Bustamante F, Brunaldi VO, Bernardo WM, de Moura DTH, de Moura ETH, Galvão M, et al. Obesity treatment with botulinum toxin-A is not effective: a systematic review and meta-analysis. Obes Surg. 2017;27(10):2716-23.  https://doi.org/10.1007/s11695-017-2857-5  PMID: 28812212 
  15. Kirchner S, Krämer KM, Schulze M, Pauly D, Jacob D, Gessler F, et al. Pentaplexed quantitative real-time PCR assay for the simultaneous detection and quantification of botulinum neurotoxin-producing clostridia in food and clinical samples. Appl Environ Microbiol. 2010;76(13):4387-95.  https://doi.org/10.1128/AEM.02490-09  PMID: 20435756 
  16. Hendrickx D, Varela Martínez C, Contzen M, Wagner-Wiening C, Janke K-H, Hernando Jiménez P, et al. First cross-border outbreak of foodborne botulism in the European Union associated with the consumption of commercial dried roach (Rutilus rutilus). Front Public Health. 2023;10:1039770.  https://doi.org/10.3389/fpubh.2022.1039770  PMID: 36684858 
  17. Stern D, von Berg L, Skiba M, Dorner MB, Dorner BG. Replacing the mouse bioassay for diagnostics and potency testing of botulinum neurotoxins – progress and challenges. Berl Munch Tierarztl Wochenschr. 2018;131(9/10):375-94.  https://doi.org/10.2376/0005-9366-17110 
  18. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1-9.  https://doi.org/10.1007/s40268-014-0077-1 
  19. Boyer AE, Moura H, Woolfitt AR, Kalb SR, McWilliams LG, Pavlopoulos A, et al. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal Chem. 2005;77(13):3916-24.  https://doi.org/10.1021/ac050485f  PMID: 15987092 
  20. Kalb SR, Baudys J, Wang D, Barr JR. Recommended mass spectrometry-based strategies to identify botulinum neurotoxin-containing samples. Toxins (Basel). 2015;7(5):1765-78.  https://doi.org/10.3390/toxins7051765  PMID: 25996606 
  21. Evans ER, Skipper PJ, Shone CC. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin. J Appl Microbiol. 2009;107(4):1384-91.  https://doi.org/10.1111/j.1365-2672.2009.04325.x  PMID: 19426271 
  22. Hallis B, James BA, Shone CC. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J Clin Microbiol. 1996;34(8):1934-8.  https://doi.org/10.1128/jcm.34.8.1934-1938.1996  PMID: 8818885 
  23. von Berg L, Stern D, Pauly D, Mahrhold S, Weisemann J, Jentsch L, et al. Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology. Sci Rep. 2019;9(1):5531.  https://doi.org/10.1038/s41598-019-41722-z  PMID: 30940836 
  24. Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, Barr JR. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. Anal Biochem. 2006;351(1):84-92.  https://doi.org/10.1016/j.ab.2006.01.027  PMID: 16500606 
  25. Wang D, Baudys J, Hoyt KM, Barr JR, Kalb SR. Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry. Anal Bioanal Chem. 2017;409(20):4779-86.  https://doi.org/10.1007/s00216-017-0421-8  PMID: 28573317 
  26. Turkish Ministry of Health General Directorate of Health Services. Basın Duyurusu. [Press release]. Ankara: TR Ministry of Health; 10 March 2023. Available from: https://shgm.saglik.gov.tr/TR,95056/basin-duyurusu.html
  27. World Health Organization (WHO). Iatrogenic botulism - European Region. Geneva: WHO; 24 March 2023. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON450
  28. European Centre for Disease Prevention and Control (ECDC). Weekly bulletin. Communicable Disease Threats Report. Week 10, 5-11 March 2023. Stockholm: ECDC. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-Disease-Threats-Report-10-Mar-2023.pdf
  29. European Centre for Disease Prevention and Control (ECDC). Weekly bulletin. Communicable Disease Threats Report. Week 12, 19-25 March 2023. Stockholm: ECDC. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-19-25-March-Week-12_0.pdf
  30. European Centre for Disease Prevention and Control (ECDC). Weekly bulletin. Communicable Disease Threats Report. Week 13, 26 March–1 April 2023. Stockholm: ECDC. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-13-2023.pdf
  31. Robert Koch Institute (RKI). Fälle von iatrogenem Botulismus nach Behandlung mit Botulinum-Neurotoxin in der Türkei. Epidemiologisches Bulletin. Berlin: RKI; 9 March 2023. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/10_23.pdf?__blob=publicationFile
  32. Robert Koch Institute (RKI). Update – Fälle von iatrogenem Botulismus nach Behandlung mit Botulinum-Neurotoxin in der Türkei. Epidemiologisches Bulletin. Berlin: RKI; 23 March 2023. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/12_23.pdf?__blob=publicationFile
  33. European Centre for Disease Prevention and Control (ECDC). Botulism cases in Europe following medical interventions with botulinum neurotoxin. Stockholm: ECDC; 14 March 2023. Available from: https://www.ecdc.europa.eu/en/news-events/botulism-cases-europe-following-medical-interventions-botulinum-neurotoxin
  34. Worbs S, Fiebig U, Zeleny R, Schimmel H, Rummel A, Luginbühl W, et al. Qualitative and quantitative detection of botulinum neurotoxins from complex matrices: results of the first international proficiency test. Toxins(Basel). 2015;7(12):4935-66.  https://doi.org/10.1007/s00216-017-0421-8  PMID: 28573317 
  35. Halai UA, Terashita D, Kim M, Green N, Kalb SR, Chatham-Stephens K, et al. Notes from the field: Intestinal colonization and possible iatrogenic botulism in mouse bioassay-negative serum specimens - Los Angeles County, California, November 2017. MMWR Morb Mortal Wkly Rep. 2018;67(43):1221-2.  https://doi.org/10.15585/mmwr.mm6743a6  PMID: 30383741 
  36. Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005;5(3):274-9.  https://doi.org/10.1016/j.coph.2004.12.006  PMID: 15907915 
  37. Bigalke H, Wohlfarth K, Irmer A, Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol. 2001;168(1):162-70.  https://doi.org/10.1006/exnr.2000.7583  PMID: 11170731 
  38. Pickett A. Counterfeit botulinum medical products and risk of bioterrorism. In: Gopalakrishnakone P, Balali-Mood M, Llewellyn L, Singh BR (editors). Toxinology: Biological Toxins and Bioterrorism. Dordrecht: Springer; 2013. p. 1-14. Available from: https://link.springer.com/referenceworkentry/10.1007/978-94-007-5869-8_28
  39. Hunt T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol. 2008;58(3):517-8.  https://doi.org/10.1016/j.jaad.2007.11.015  PMID: 18280358 
  40. Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009;61(1):149-50.  https://doi.org/10.1016/j.jaad.2008.12.042  PMID: 19539854 
  41. Rashid EAMA, El-Mahdy NM, Kharoub HS, Gouda AS, ElNabarawy NA, Mégarbane B. Iatrogenic botulism outbreak in Egypt due to a counterfeit botulinum toxin A preparation - A descriptive series of patient features and outcome. Basic Clin Pharmacol Toxicol. 2018;123(5):622-7. https://doi.org/10.1111/bcpt.13048  PMID: 29786953 
  42. World Health Organization (WHO). Medical Product Alert N°4/2022: Falsified DYSPORT. Falsified DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) identified in the WHO Regions of Europe and Eastern Mediterranean. Geneva: WHO; 19 August 2022. Available from: https://www.who.int/news/item/19-08-2022-medical-product-alert-n-4-2022-falsified-dysport
  43. Alster TS, Harrison IS. Alternative clinical indications of botulinum toxin. Am J Clin Dermatol. 2020;21(6):855-80.  https://doi.org/10.1007/s40257-020-00532-0  PMID: 32651806 
  44. Rollnik JD, Meier PN, Manns MP, Göke M. Antral injections of botulinum A toxin for the treatment of obesity. Ann Intern Med. 2003;138(4):359-60.  https://doi.org/10.7326/0003-4819-138-4-200302180-00026  PMID: 12585845 
  45. Topazian M, Camilleri M, De La Mora-Levy J, Enders FB, Foxx-Orenstein AE, Levy MJ, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008;18(4):401-7.  https://doi.org/10.1007/s11695-008-9442-x  PMID: 18286347 
  46. Albani G, Petroni ML, Mauro A, Liuzzi A, Lezzi G, Verti B, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40(8):833-5.  https://doi.org/10.1007/s00535-005-1669-x  PMID: 16143889 
  47. Gui D, Mingrone G, Valenza V, Spada PL, Mutignani M, Runfola M, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675-80.  https://doi.org/10.1111/j.1365-2036.2006.02773.x  PMID: 16480407 
  48. Júnior AC, Savassi-Rocha PR, VazCoelho LG, Spósito MM, Albuquerque W, Diniz MT, et al. Botulinum A toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16(3):335-43.  https://doi.org/10.1381/096089206776116408  PMID: 16545166 
/content/10.2807/1560-7917.ES.2023.28.23.2300203
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error